 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1902 News |  |
| «12...891011121314151617181920» |
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg. (clinicaltrials.gov) - Aug 7, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
PK/PD data, Journal: Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination. (Pubmed Central) - Aug 7, 2019
When comparing the AUC and C of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence.
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed: An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I) (clinicaltrials.gov) - Aug 7, 2019
P1, N=48, Active, not recruiting, Sponsor: LG Chem
When comparing the AUC and C of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence. Not yet recruiting --> Active, not recruiting
- || Fotivda (tivozanib) / EUSA Pharma, AVEO
$AVEO Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights. https://t.co/2a8mZW0Unl (Twitter) - Aug 1, 2019
- | CUE-101 / Cue Biopharma, LG Chem
Enrollment open, Combination therapy, Monotherapy, Metastases: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 31, 2019
P1, N=50, Recruiting, Sponsor: Cue Biopharma
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Zarnestra (tipifarnib) / Kura Oncology, Fotivda (tivozanib) / EUSA Pharma, AVEO
Clinical, FDA event: But what about the agents that fall just short of approval in refractory patients: tivozanib, tipifarnib, decitabine, clofarabine.... Why not allow patients to use those drugs? Those who disagree can opt not to use them. Why does the FDA get to decide these are not good enough? (Twitter) - Jul 6, 2019
- | Shinbaro (GCSB-5) / Green Cross, LG Chem
Clinical, Journal: The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study. (Pubmed Central) - Jun 27, 2019
This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758).
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Jun 25, 2019
P2, N=5, Active, not recruiting, Sponsor: Massachusetts General Hospital
1604-138-758). Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Fotivda (tivozanib) / EUSA Pharma, AVEO
Clinical, Review, Journal: Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. (Pubmed Central) - Jun 14, 2019
Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.
- | Lantus (insulin glargine) / Sanofi, Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment open, Trial completion date: Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 11, 2019
P4, N=100, Recruiting, Sponsor: Nanjing First Hospital, Nanjing Medical University
This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape. Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> Jul 2019
- | CUE-101 / Cue Biopharma, LG Chem
New P1 trial, Combination therapy, Monotherapy, Metastases: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 6, 2019
P1, N=50, Not yet recruiting, Sponsor: Cue Biopharma
- |||||| Fotivda (tivozanib) / EUSA Pharma, AVEO, Nexavar (sorafenib) / Bayer, Amgen
Clinical: 🚩POSTER SESSION @ASCO #ASCO19 📆Monday 🕐 TIVO-3 trial #CamilloPorta @BernardEscudier @montypal @brian_rini Tivozanib improved PFS vs. sorafenib, especially for pts w favorable & intermediated IMDC risk https://t.co/7BkhtSOSzA (Twitter) - Jun 3, 2019
- ||||| tigulixostat (LC350189) / LG Chem
New P2 trial: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Apr 30, 2019
P2, N=228, Not yet recruiting, Sponsor: LG Chem
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Fotivda (tivozanib) / EUSA Pharma, AVEO
#AVEOOncology Announces $2M Milestone Payment From #EUSAPharma Related To Commercialization of #FOTIVDA® in Spain $AVEO https://t.co/8qsuvENYI9 (Twitter) - Apr 25, 2019
- || tigulixostat (LC350189) / LG Chem
New P1 trial: The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. (clinicaltrials.gov) - Apr 24, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- || ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Apr 19, 2019
P1b, N=14, Completed, Sponsor: James J Lee
Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> Jul 2019 Active, not recruiting --> Completed
- | Fotivda (tivozanib) / EUSA Pharma, AVEO
Journal: The role of tivozanib in advanced renal cell carcinoma therapy. (Pubmed Central) - Apr 11, 2019
Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
New P4 trial: A Food Effect Study of Besifovir in Healthy Subjects (clinicaltrials.gov) - Mar 22, 2019
P4, N=15, Completed, Sponsor: IlDong Pharmaceutical Co Ltd
- || ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
New P1 trial: BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination. (clinicaltrials.gov) - Mar 8, 2019
P1, N=48, Not yet recruiting, Sponsor: LG Chem
- | ficlatuzumab (AV-299) / LG Chem
Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Mar 7, 2019
P1, N=24, Recruiting, Sponsor: C. Babis Andreadis
Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting. Trial primary completion date: Jun 2019 --> Dec 2019
- || Gemiglo (gemigliptin) / Sanofi, LG Chem
New P1 trial: An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I) (clinicaltrials.gov) - Mar 6, 2019
P1, N=48, Not yet recruiting, Sponsor: LG Chem
- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P3 trial: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study) (clinicaltrials.gov) - Feb 15, 2019
P3, N=314, Not yet recruiting, Sponsor: LG Chem
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial completion, Trial completion date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jan 25, 2019
P4, N=132, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2019 --> Dec 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017
- ||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin (clinicaltrials.gov) - Jan 24, 2019
P=N/A, N=5180, Completed, Sponsor: LG Life Sciences
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017 Active, not recruiting --> Completed
- ficlatuzumab (AV-299) / LG Chem
Biomarker, Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases: Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 3, 2019
P1b, N=1, Terminated, Sponsor: Julie E. Bauman, MD, MPH
Active, not recruiting --> Completed Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Dec 11, 2018
P2, N=5, Active, not recruiting, Sponsor: Massachusetts General Hospital
Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
Trial completion date, Trial primary completion date: Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues (clinicaltrials.gov) - Nov 29, 2018
P3, N=244, Recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Dec 2017 --> Feb 2020 | Trial primary completion date: Dec 2017 --> Mar 2019
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion date, Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 24, 2018
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial completion date: Dec 2017 --> Feb 2020 | Trial primary completion date: Dec 2017 --> Mar 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019
- | Hyruan (sodium hyaluronate) / LG Chem
Enrollment open: Intraarticular Glucose Versus Hyaluronic Acid Injection for Knee Osteoarthrosis (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=100, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- | Hyruan (sodium hyaluronate) / LG Chem
Enrollment open: What Factors Are Associated With Prognosis of Rotator Cuff Disorder After Subacromial Hyaluronic Acid Injection (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=200, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Hyruan (sodium hyaluronate) / LG Chem
New trial: Intraarticular Glucose Versus Hyaluronic Acid Injection for Knee Osteoarthrosis (clinicaltrials.gov) - Oct 1, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
- | Hyruan (sodium hyaluronate) / LG Chem
New trial: What Factors Are Associated With Prognosis of Rotator Cuff Disorder After Subacromial Hyaluronic Acid Injection (clinicaltrials.gov) - Sep 19, 2018
P=N/A, N=200, Not yet recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial completion date, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Aug 21, 2018
P2, N=58, Completed, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> Dec 2016
- | Lantus (insulin glargine) / Sanofi, Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
New P4 trial: Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 14, 2018
P4, N=100, Not yet recruiting, Sponsor: Nanjing First Hospital, Nanjing Medical University
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Trial primary completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=28, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Mar 2019
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 8, 2018
P3, N=322, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Sep 2018 --> Dec 2018
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 3, 2018
P3, N=322, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Trial primary completion date: Sep 2018 --> Dec 2018 Trial completion date: Oct 2018 --> Dec 2019
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
New P4 trial: Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver (clinicaltrials.gov) - Jul 27, 2018
P4, N=76, Not yet recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
- ||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Trial completion, Trial primary completion date: A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) (clinicaltrials.gov) - Jul 6, 2018
P3, N=148, Completed, Sponsor: LG Life Sciences
Trial completion date: Oct 2018 --> Dec 2019 Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Trial completion date, Combination therapy, Metastases: TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) - Jun 26, 2018
P1/2, N=28, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018
- | ficlatuzumab (AV-299) / LG Chem
Trial completion date, Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Jun 25, 2018
P1, N=24, Recruiting, Sponsor: C. Babis Andreadis
Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
- |||||||||| Follitrope (recombinant human follicle stimulating hormone) / LG Chem
New P3 trial: Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women. (clinicaltrials.gov) - Apr 24, 2018
P3, N=451, Completed, Sponsor: Hangzhou YuYuan Bioscience Technology Co., Ltd.
- | LR19122 / LG Chem
Trial completion: A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (clinicaltrials.gov) - Apr 13, 2018
P1, N=42, Completed, Sponsor: LG Chem
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed
- | MIT-001 / MitoImmune Therap
Trial completion: A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. (clinicaltrials.gov) - Apr 11, 2018
P1, N=32, Completed, Sponsor: LG Chem
Active, not recruiting --> Completed Recruiting --> Completed
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Enrollment change: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Apr 5, 2018
P1, N=230, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=350 --> 230
- ||||| Besivo (besifovir) / Gilead, LG Chem, Ildong
Enrollment closed, Trial completion date: Phase 3 and Extensional Study of Besifovir (clinicaltrials.gov) - Mar 20, 2018
P3, N=197, Active, not recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
N=350 --> 230 Recruiting --> Active, not recruiting | Trial completion date: Jan 2016 --> Jan 2023
- || Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 1, 2018
P2, N=54, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting | Trial completion date: Jan 2016 --> Jan 2023 Trial primary completion date: Jan 2018 --> Jan 2019
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion, Trial initiation date, Trial primary completion date: BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Feb 22, 2018
P1, N=70, Completed, Sponsor: LG Chem
Trial primary completion date: Jan 2018 --> Jan 2019 Not yet recruiting --> Completed | Initiation date: Dec 2017 --> Dec 2017 | Trial primary completion date: Jan 2018 --> Jan 2018
- | Avastin (bevacizumab) / Roche, onartuzumab (RG3638) / Roche
Biomarker, Clinical, P2 data, Journal: A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. (Pubmed Central) - Feb 19, 2018
P2
MET immunohistochemistry was not a predictive biomarker. It remains to be seen if other biomarkers or small molecule inhibitors may be more appropriate for inhibiting this oncogenic pathway.